Supernus Pharmaceuticals (SUPN) Interest Expenses (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Interest Expenses of $2.3 million for Q2 2026, up 961.93% year-over-year from $218000.0 in Q2 2025, and down 43.51% on a QoQ basis from $4.1 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Interest Expenses (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Interest Expenses for 16 years, with the latest figure at $2.3 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $2.3 million, up 961.93% year-over-year; the trailing twelve-month figure through Jun 2026 was -$4.1 million (down 1985.32% YoY), and the FY2025 annual result was $590.2 million, up 784.56% from the prior year.
- Interest Expenses declined to $2.3 million in Q2 2026, from $4.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $75.0 million in Q1 2022 and troughed at -$14.4 million in Q4 2025.
- A 5-year average of $8.6 million and a median of $1.6 million in 2022 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2022, when Interest Expenses jumped 1270.04%; it then sank 98.79% in 2023.
- A 5-year view of Interest Expenses shows it stood at $1.6 million in 2022, then declined by 1.94% to $1.6 million in 2023, then tumbled by 946.07% to -$13.2 million in 2024, then decreased by 9.01% to -$14.4 million in 2025, then surged by 116.06% to $2.3 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $2.3 million in Q2 2026, $4.1 million in Q1 2026, and -$14.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 59.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Mn |
| Jun 30, 2026 | 2.32 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2025 | -14.42 Mn |
| Dec 31, 2025 | -14.42 Mn |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 218,000.00 |
| Jun 30, 2025 | 218,000.00 |
| Mar 31, 2025 | 3.89 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | 107,000.00 |
| Sep 30, 2024 | 107,000.00 |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Mar 31, 2024 | 4.00 Mn |